London English news | London, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

London, Dec 23 A third dose of AstraZeneca's Covid vaccine, named Covishield in India, produces similar neutralising antibody levels against Omicron as after two doses against the Delta variant, according to a new study led by the Oxford University who developed the vaccine.The yet-to-be peer-reviewed study showed that the levels of neutralisation titres for Omicron seen after the third dose booster were higher than the neutralising antibodies found in individuals who had been previously infected with and recovered naturally from Covid-19 Alpha, Beta, Delta variants and original strain.Sera obtained from individuals one month after receiving the third dose booster vaccination neutralised the Omicron variant to levels that were broadly similar to those observed one month after the second dose against the Delta variant.The study analysed blood samples taken from individuals infected with Covid-19; those who had been vaccinated with a two-dose schedule and a third dose booster; and those who had reported previous infection from other Covid-19 variants of concern. The study included samples from 41 individuals who had received three doses of AstraZeneca vaccine, and 20 individuals that had received three doses of Pfizer."It is very encouraging to see that current vaccines have the potential to protect against Omicron following a third dose booster," said John Bell, Professor of Medicine at University of Oxford in a statement."These results support the use of third dose boosters as part of national vaccine strategies, especially to limit the spread of variants of concern, including Omicron, said John Bell, Professor of Medicine at University of Oxford in a statement.The drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on developing the vaccine with AstraZeneca.Meanwhile, Oxford University and AstraZeneca announced that they have begun the work to develop a Covid shot that specifically targets the new strain."Like with many previous variants of concern, and together with our partners AstraZeneca, we have taken preliminary steps in producing an updated vaccine in case it is needed," Sandy Douglas, a research group leader at Oxford, was quoted as saying to the Financial Times.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

LondonFOLLOW

London, Latest News

As Christmas is around the corner, everyone is preparing for the festive season in their own way. You might be thinking of cosying up with your family and friends with some hot cocoa but that's not the only option you have. ...

London, Dec 24 British-Swedish drugmaker AstraZeneca has announced that its antibody drug 'Evusheld' is effective against the new ... ...

Indian javelin star Neeraj Chopra, who created history by winning a gold medal for India at the Tokyo Olympics, has turned 24 on Friday. ...

UK Home Minister Priti Patel on Thursday condemned a "seriously disturbing" anti-Semitic attack in north London, and said she was in close contact with the Metropolitan Police and a charity protecting the Jewish community in the UK. ...

Coldplay's lead singer Chris Martin has confirmed that the legendary band will stop playing music in 2025. ...

London, Dec 23 Children aged 5 to 11 are three times more at risk of Covid infections as ... ...

Arcesium LLC, a leading global financial technology and professional services firm, announced today that it has expanded its India-based operations with a new office in Delhi NCR. ...

London, Dec 23 A third dose of AstraZeneca's Covid vaccine, named Covishield in India, produces similar neutralising antibody ... ...